Publications by authors named "Josie Montegaard"

Claim this Profile
E
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva, Josie Montegaard

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva, Josie Montegaard

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
Inhye E Ahn, Danielle M Brander, Yue Ren, Yinglu Zhou, Svitlana Tyekucheva, Josie Montegaard

Blood Adv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care.
Mary Ann Anderson, Renata Walewska, Fidelma Hackett, Arnon P Kater, Josie Montegaard

Cancers (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Matthew S Davids, Kerry A Rogers, Svitlana Tyekucheva, Zixu Wang, Samantha Pazienza, Josie Montegaard

Blood· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Matthew S Davids, Benjamin L Lampson, Svitlana Tyekucheva, Zixu Wang, Jessica C Lowney, Josie Montegaard

Lancet Oncol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
Matthew S Davids, David C Fisher, Svitlana Tyekucheva, Mikaela McDonough, John Hanna, Josie Montegaard

Leukemia· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis